摘要 |
<p>Use of at least one peptide (I) comprising a fragment of protein S of corona virus having a 365 amino acid sequence (S5), given in the specification, having at least 12 amino acids or a fragment of at least 36 nucleotides from a 1095 base pair sequence (S1), given in the specification, that encodes (I), for preparation of a vaccine that protects against coronavirus infection, is new. Independent claims are also included for: (1) peptide (Ia) comprising a 21 (S2), 59 (S3), or 31 (S4) amino acid sequence, given in the specification, and their fragments of 12-20 residues; (2) modified peptides (Ib) derived from (Ia) by artificial mutation, deletion, insertion and/or variation, provided that they do not induce facilitation; (3) vaccine for protection against coronavirus (CV) infection that contains at least one (Ia) or (Ib) and carrier, adjuvant and/or vehicle; (4) nucleic acid (IIa) that encodes (Ia) or (Ib); (5) recombinant vector containing (IIa); (6) vaccine against CV infection that contains (IIa) or the vector of (5); and (7) selecting immunogenic peptides from CV protein that do not induce facilitation.</p> |